21 results about "Endocrine functions" patented technology

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

A hydrogel includes the crosslinked dextran polymer of the invention and / or a hydrogel that further includes biological cells. The hydrogel has a therapeutic use for treating a disorder or disease in a mammal wherein the disorder or disease is due to lack or malfunction of endocrine function of pancreas organ. An implant includes the hydrogel and further includes a ring and a net.

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

This invention belongs to the field of biomedicine, and specifically relates to the application of FeTMPyP in the preparation of drugs to alleviate ovarian toxicity. This application addresses the issue that combined exposure to MC-LR and NaNO₂ significantly induces nitrification stress in mouse ovaries, leading to follicular barrier disruption and ovarian reproductive endocrine dysfunction. FeTMPyP was selected as an intervention agent, which effectively alleviated nitrification stress induced by combined exposure to MC-LR and NaNO₂ in mouse ovaries, and improved sex hormone disorders, estrous cycle irregularities, and follicular atresia caused by the combined exposure to these two toxins. Simultaneously, it restored the fertility of mice, indicating that FeTMPyP intervention can alleviate ovarian toxicity induced by combined exposure to MC-LR and NaNO₂ in mice. This invention can be used to prepare drugs to prevent and treat diseases related to ovarian toxicity caused by environmental toxin exposure in mice, providing a new approach for the early identification and targeted intervention of ovarian-related diseases.

The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and / or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism / endocrine function disorders or neurological diseases.

The present application provides a preparation method of ganoderma triterpene and its application in preparing an antidepressant, the prepared ganoderma triterpene has clear material basis, stable component composition and controllable preparation process, the ganoderma triterpene can improve stress-induced abnormal behavior, protect hippocampus and intestinal tissue structure, regulate inflammatory response, neuroendocrine function and various neurotransmitter homeostasis, and realize the synergistic regulation of the intestinal-brain axis function by regulating the intestinal flora structure and its metabolites. The present application provides an implementable technical solution for the application of ganoderma triterpene in functional food or natural antidepressant preparation.

A novel medical use of ingenol HEP14, a dosage form of an HEP14-based drug, and a preparation method for the dosage form. The dosage form of the HEP14-based drug is an HEP14 / PLGA microsphere sustained-release dosage form formed by encapsulating the HEP14-based drug with a polylactic acid-glycolic acid copolymer, and has the functions of high HEP14 drug loading rate, high encapsulation rate, and long-acting HEP14 sustained-release. It has been found for the first time that HEP14 can promote production and autophagy of mitochondria in cells and enhance the function of mitochondria in cells, promote the secretion of antioxidant enzymes and remove reactive oxygen species, promote the growth and viability of ovarian follicle granulosa cells and restore the growth and viability of aging granules, promote the secretion of angiogenic factors, reduce the fibrosis of ovarian tissues, promote the angiogenesis of ovarian tissues, and promote the regeneration of aged ovarian follicles and ovarian endocrine functions, and thus has a good effect of treating and / or preventing related diseases caused by mitochondrial dysfunction, especially the effect of treating age-related ovarian decline.

This invention discloses a post-natal plant polypeptide compound preparation for regulating endocrine function and nourishing the ovaries, which, by mass percentage, consists of the following components: 60.0%–75.0% purified water, 3.0%–6.0% lactic acid bacteria fermentation lysate, 2.0%–4.0% L-arabinose, 1.5%–3.5% double-petaled red rose extract, 1.0%–3.0% cordyceps extract, 1.0%–2.5% γ-aminobutyric acid, 1.5%–3.0% red ginseng concentrate, 1.0%–2.5% cranberry fruit powder, 0.5%–2.0% turmeric extract, and vitamin C. The ingredients include 0.5%–1.5%, frog polypeptide powder 1.0%–3.0%, carob extract 1.0%–2.5%, roselle extract 0.5%–2.0%, tremella polysaccharide 0.5%–2.0%, and yeast β-glucan 0.5%–2.0%; the sum of the mass percentages of each ingredient is 100%. The ingredients of this invention work synergistically to exert multiple effects such as endocrine regulation, uterine and ovarian care, pelvic floor muscle repair, and skin firming and moisturizing, solving the problems of single efficacy and poor synergy in existing preparations.

The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and / or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism / endocrine function disorders or neurological diseases.

The present application relates to a hydrogel for cell therapy. The invention relates to a hydrogel comprising a cross-linked dextran polymer according to the invention, and / or further comprising biological cells. It further relates to the therapeutic use of a hydrogel according to the invention for the treatment of a condition or disease in a mammal, wherein the condition or disease is due to a lack of or dysfunction of the endocrine function of the pancreatic organ, and to an implant comprising a hydrogel according to the invention. It further relates to an implant comprising a hydrogel according to the invention and further comprising a loop and a mesh.

The application discloses application of an HDAC inhibitor MS-275 in preparation of an ovarian function protection drug and belongs to the technical field of biology and pharmacy. The application finds that MS-275 can safely and effectively improve the endocrine function of ovaries, ovarian reserve, fertility and the like of mice in a drug protection group. Therefore, the application proposes that MS-275 can delay ovarian aging, and plays an important role in delaying ovarian aging and / or repairing ovarian damage and / or improving ovarian reserve function and / or reconstructing ovarian function and the like.

The invention relates to lactobacillus crispatus capable of relieving ovarian function decline and application of the lactobacillus crispatus, and belongs to the technical field of biological medicine. The invention provides a lactobacillus crispatus strain, the preservation number of the lactobacillus crispatus strain is CGMCC No.36731, and the lactobacillus crispatus strain is commercially named as lactobacillus crispatus XA-02D; the strain can improve the level of an anti-aging marker (NAD +) in an ovary of an ovarian function decline model mouse, reverse ovarian atrophy of the ovarian function decline model mouse, reverse estrus cycle disorder of the ovarian function decline model mouse, protect the ovarian reserve function of the ovarian function decline model mouse, and improve the ovarian function decline of the ovarian function decline model mouse. Compared with the prior art, the strain has the advantages of improving endocrine dysfunction of an ovarian function decline model mouse and activating a synthetic pathway of an anti-aging marker in an ovary of the ovarian function decline model mouse, so that the strain can effectively relieve typical symptoms of ovarian function decline and has the functions of treating ovarian reserve hypofunction, premature ovarian insufficiency and premature ovarian failure.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The present application relates to the technical field of functional food, in particular to a sturgeon ovary peptide with endocrine function regulation and a preparation method thereof, which comprises the following steps: taking sturgeon ovary tissue, removing fat and impurities; adding deionized water and sodium ascorbate, homogenizing and vacuum defoaming to obtain a pretreated liquid; adding compound protease to the pretreated liquid for enzymolysis; after the enzymolysis is completed, centrifugal separation is carried out on the supernatant after cooling; the supernatant is separated through an ultrafiltration membrane, and then a low-temperature microwave-assisted oxidation cross-linking reaction is carried out, and hydrogen peroxide and a mixture of naringin / soy isoflavones are added; finally, vacuum freeze-drying is carried out to obtain the sturgeon ovary peptide with endocrine function regulation. In the present application, the microwave-assisted oxidation cross-linking and the incorporation of naringin and soy isoflavones significantly reduce the oxidation loss in the high-temperature drying process, further stabilize the active conformation and enhance the binding affinity to the estrogen receptor.

This invention discloses an acupoint electroacupuncture microcurrent combination therapy device for regulating endocrine function, belonging to the technical field of acupoint electroacupuncture therapy devices. It includes a therapy device housing with a microcurrent circuit inside; a switch and multiple knobs, all located on the panel of the therapy device housing, the switch controlling the on / off state of the therapy device; multiple electroacupuncture connecting wires, arranged in an equidistant array on the side wall of the therapy device housing, the intensity of the microcurrent released by the connecting wires controlled by the knobs; and an adsorption component and a limiting component. The adsorption component ensures the therapy device can be quickly and stably fixed on a flat contact surface, providing good adsorption and sealing, and preventing displacement, thus preventing the electroacupuncture from detaching from the acupoint during treatment and ensuring the continuity of treatment. The limiting component precisely limits the electroacupuncture connecting wires, preventing them from being pulled off, and effectively protecting the connection points, avoiding any impact on the treatment effect due to loose connecting wires.

The invention relates to the technical field of biological medicines, in particular to application of an MT-CO2 gene inhibitor in preparation of a medicine for treating organ injury diseases. Experimental evidences show that MT-CO2 mRNA can be actively secreted to extracellular gaps and whole body circulatory systems, is widely distributed among tissues and organs and plays a unique regulation function. This discovery establishes the status of mitochondria as a novel endocrine organelle, which endows it with the ability to generate and release hereditary endocrine media into systemic circulation, thereby redefining all mitochondrial-containing cells as potential endocrine cells. The endocrine-like function of the mRNA outside the mitochondria reveals an important mechanism of interorgan communication and cell reprogramming, and opens up a brand new view for endocrine biology research. MT-CO2 is associated with various organ injury diseases, and expression of DYNC2H1 is interfered by an MT-CO2 gene inhibitor, so that the organ injury diseases are treated. The invention opens up a brand new target for treatment of various human diseases.

The invention relates to a female qi and blood regulating tonic based on a deer uterus and ovary extract and a preparation method thereof, and belongs to the technical field of health food. The qi and blood regulating tonic for women comprises the following components in percentage by weight: 20-25% of sika deer uterus extract, 15-20% of sika deer ovary extract, 15-20% of sika deer antler blood extract, 10-15% of red ginseng, 8-12% of angelica sinensis, 8-12% of cinnamon, 5-8% of astragalus membranaceus, 5-8% of fennel, 5-8% of poria cocos, 3-5% of fructus lycii and 3-5% of Chinese dates. According to the invention, the deer-derived extract and the traditional Chinese medicines are scientifically combined to synergistically exert the effects of tonifying qi and blood, regulating menstruation, improving internal secretion and assisting reproductive health, and the composition is suitable for pregnant women, postpartum women or weak women; meanwhile, a preparation method of various dosage forms is provided, the process is stable and controllable, the retention rate of effective components is high, and the use requirements of different people are met.

The invention belongs to the technical field of biomedicine and regenerative medicine, and particularly relates to tissue gel with a kidney tissue endocrine recovery function and a preparation method of the tissue gel. The tissue gel is formed by mixing a renal cortex tissue in a hydrogel matrix material; the mass ratio of the hydrogel matrix material to the renal cortex tissue is (1-10): 1; preferably, the hydrogel matrix material is selected from one or a mixture of more than two of sodium alginate, gelatin, hyaluronic acid, collagen, fibrin, polyethylene glycol and polylactic acid-glycolic acid copolymer. The tissue gel disclosed by the invention realizes long-term survival and functional reconstruction of ectopic kidney tissues in the spleen, has the characteristics of simplicity and convenience in operation, high success rate and large clinical transformation potential, and can provide a new treatment strategy for renal failure and endocrine defect diseases.

The invention relates to a formula, a preparation method, a product and an application of children health-care growth-promoting paste. The formula comprises the following components: 25-35 g of Chinese yam, 8-10 g of American ginseng, 10-14 g of poria cocos, 16-24 g of bighead atractylodes rhizome, 8-12 g of endothelium corneum gigeriae galli, 16-20 g of fried burdock, 16-24 g of radix scrophulariae, 14-18 g of mulberry leaves, 8-12 g of tortoise-shell glue, 8-12 g of prepared polygala tenuifolia, 16-24 g of calcined dragon bone, 5-8 g of rhizoma acori graminei and 8-12 g of astragalus membranaceus. According to the ointment formula, the traditional Chinese medicine theory of treating spleen and kidney at the same time and regulating mind and body is innovatively converted into practice, physique and intelligence development of children is promoted through multi-target intervention, and meanwhile common diseases are prevented. The ointment comprehensively improves spleen and stomach functions, promotes growth hormone secretion, sleep quality and endocrine functions, and provides comprehensive support for growth and development of children. The ointment not only aims at diseases, but also focuses on conditioning physique, and enhances the immunity of the next year in combination with the opportunity that yang qi starts to grow in winter solstice.